180 Life Sciences (ATNF) Competitors $1.00 +0.01 (+1.01%) As of 03:47 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATNF vs. XFOR, CYTH, OVID, IMNN, GDTC, CASI, LSTA, ENLV, QTTB, and MIRAShould you be buying 180 Life Sciences stock or one of its competitors? The main competitors of 180 Life Sciences include X4 Pharmaceuticals (XFOR), Cyclo Therapeutics (CYTH), Ovid Therapeutics (OVID), Imunon (IMNN), CytoMed Therapeutics (GDTC), CASI Pharmaceuticals (CASI), Lisata Therapeutics (LSTA), Enlivex Therapeutics (ENLV), Q32 Bio (QTTB), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry. 180 Life Sciences vs. Its Competitors X4 Pharmaceuticals Cyclo Therapeutics Ovid Therapeutics Imunon CytoMed Therapeutics CASI Pharmaceuticals Lisata Therapeutics Enlivex Therapeutics Q32 Bio MIRA Pharmaceuticals 180 Life Sciences (NASDAQ:ATNF) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, community ranking, earnings, dividends, profitability, analyst recommendations, valuation and risk. Is ATNF or XFOR more profitable? X4 Pharmaceuticals' return on equity of -236.19% beat 180 Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A -558.93% -54.10% X4 Pharmaceuticals N/A -236.19%-75.14% Do analysts recommend ATNF or XFOR? X4 Pharmaceuticals has a consensus price target of $72.33, suggesting a potential upside of 2,271.58%. Given X4 Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe X4 Pharmaceuticals is more favorable than 180 Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00X4 Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in ATNF or XFOR? 4.1% of 180 Life Sciences shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 0.2% of 180 Life Sciences shares are owned by company insiders. Comparatively, 2.4% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more volatility and risk, ATNF or XFOR? 180 Life Sciences has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Does the MarketBeat Community prefer ATNF or XFOR? X4 Pharmaceuticals received 78 more outperform votes than 180 Life Sciences when rated by MarketBeat users. Likewise, 68.38% of users gave X4 Pharmaceuticals an outperform vote while only 14.29% of users gave 180 Life Sciences an outperform vote. CompanyUnderperformOutperform180 Life SciencesOutperform Votes214.29%Underperform Votes1285.71% X4 PharmaceuticalsOutperform Votes8068.38% Underperform Votes3731.62% Which has better earnings & valuation, ATNF or XFOR? 180 Life Sciences has higher earnings, but lower revenue than X4 Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/A-$19.93MN/AN/AX4 Pharmaceuticals$31.36M0.56-$101.17M$2.141.43 Does the media favor ATNF or XFOR? In the previous week, X4 Pharmaceuticals had 4 more articles in the media than 180 Life Sciences. MarketBeat recorded 7 mentions for X4 Pharmaceuticals and 3 mentions for 180 Life Sciences. 180 Life Sciences' average media sentiment score of 1.89 beat X4 Pharmaceuticals' score of 0.65 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 180 Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive X4 Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryX4 Pharmaceuticals beats 180 Life Sciences on 11 of the 14 factors compared between the two stocks. Get 180 Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATNF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNF vs. The Competition Export to ExcelMetric180 Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.70M$6.94B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E RatioN/A8.7927.2619.97Price / SalesN/A263.06412.06157.64Price / CashN/A65.8538.2534.64Price / Book-4.176.597.064.69Net Income-$19.93M$144.20M$3.24B$248.14M7 Day Performance-4.76%3.81%2.56%2.39%1 Month Performance-9.09%11.10%8.75%6.06%1 Year Performance-35.06%3.95%31.30%13.57% 180 Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNF180 Life SciencesN/A$1.00+1.0%N/A-36.1%$5.70MN/A0.007News CoveragePositive NewsAnalyst ForecastXFORX4 Pharmaceuticals4.3593 of 5 stars$4.14-3.7%$72.33+1,647.2%-89.8%$23.97M$31.36M-45.9980Short Interest ↑Analyst RevisionCYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870.73K-0.809OVIDOvid Therapeutics4.3753 of 5 stars$0.33+4.0%$2.78+740.4%-89.7%$23.55M$548K-0.7060News CoverageHigh Trading VolumeIMNNImunon1.9421 of 5 stars$1.33-8.9%$15.50+1,065.4%+29.7%$23.33M$500K-0.7030Short Interest ↑Gap DownGDTCCytoMed Therapeutics2.6094 of 5 stars$2.12+3.2%$5.00+136.4%+2.9%$23.14M$69.50K0.00N/APositive NewsGap UpCASICASI Pharmaceuticals4.392 of 5 stars$1.86-0.4%$4.00+115.6%-44.7%$22.82M$31.37M-0.83180LSTALisata Therapeutics2.4667 of 5 stars$2.63-2.2%$15.00+470.3%-33.0%$22.66M$1M-1.0530News CoverageGap UpENLVEnlivex Therapeutics3.4669 of 5 stars$0.94-2.8%$10.00+963.8%-33.7%$22.23MN/A-0.9670News CoverageUpcoming EarningsQTTBQ32 Bio3.4341 of 5 stars$1.82-4.2%$24.71+1,257.9%-91.5%$22.20M-$6.65M-0.1339Positive NewsShort Interest ↓MIRAMIRA Pharmaceuticals3.3749 of 5 stars$1.29-7.9%$14.00+985.3%+61.3%$21.83MN/A-2.302Short Interest ↓ Related Companies and Tools Related Companies XFOR Competitors CYTH Competitors OVID Competitors IMNN Competitors GDTC Competitors CASI Competitors LSTA Competitors ENLV Competitors QTTB Competitors MIRA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATNF) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 180 Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share 180 Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATNF Stock Free ATNF Stock Alerts